Zhitong Finance App News, Shanghai Pharmaceutical (601607.SH) issued an announcement. Recently, Shanghai Shangyao Ruier Pharmaceutical Co., Ltd., a subsidiary of the company, received the approval and issuance of the “Pharmaceutical Clinical Trial Approval Notice” for triprostenil diethanolamine inhalation powder from the State Drug Administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.